April 26th 2024
A study finds that despite the development of some new agents for highly-resistant pathogens, prescribers are reluctant to utilize these therapies.
What’s New in 2022 From the CLSI Subcommittee on Antimicrobial Susceptibility Testing
October 26th 2022The Clinical and Laboratory Standards Institute Subcommittee on Antimicrobial Susceptibility Testing held a virtual winter meeting and a hybrid summer meeting in 2022. Ad hoc working groups have several breakpoint revisions underway for multiple organism-drug combinations.
Read More
Antibiotics for S aureus Bacteremia Adapted to Patient's Access to Treatment
October 5th 2022Oral antibiotics after partial completion of intravenous regimen for S aureus bacteremia improves outcomes of persons who inject drugs (PWID), which is a population that often has limited access to treatment.
Read More
The Role of Pharmacists in the World of Pediatric Antimicrobial Stewardship
September 27th 2022The limitation in the number of pediatric-specific guidelines by professional organizations, and results from large randomized clinical trials, may place an additional emphasis on literature evaluation skills for pediatric ASP pharmacists.
Read More
FDA Committee Recommends Approval for Rebyota (RBX2660) to Treat Recurrent C Difficile
September 22nd 2022The Vaccines and Related Biological Products Advisory Committee's (VRBPAC) positive vote follows the committee’s review of the data from the biologics license application (BLA) for RBX2660.
Read More